Literature DB >> 14590205

Neuropsychological profile of a large kindred with familial Alzheimer's disease caused by the E280A single presenilin-1 mutation.

A Ardila1, F Lopera, M Rosselli, S Moreno, L Madrigal, J C Arango-Lasprilla, M Arcos, C Murcia, J C Arango-Viana, J Ossa, A Goate, K S Kosik.   

Abstract

It was hypothesized that subjective memory complaints represent the earliest sign of dementia in carriers of the presenilin-1 (PS1) mutation. A total of 122 subjects (44 males, 78 females) were included in this study. Forty of them were positive for the mutation in the PS1 gene (mutation positive, MP) whereas 82 showed negative results (mutation negative, MN). Subjects were active, functionally normal, even though some of them complained of memory difficulties. Two groups of neuropsychological instruments were administered: (a) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neuropsychological test battery (Morris et al., 1989), and (b) some additional neuropsychological tests (Raven Test, Wechsler Memory Scale, Rey-Osterrieth Complex Figure, Boston Naming Test, Naming of Categories, Boston Diagnostic Aphasia Examination, Memory of Three Phrases, Knopman Test, Digit Symbol, and Visual "A" Cancellation Test). Performance in both groups was quite similar. In a secondary analysis, the MP group was subdivided into two subgroups: without and with memory complaints. When comparing both subgroups, a better performance in the first subgroup was found throughout the different subtests. Statistically significant differences were observed in the following test scores: Mini-Mental State Examination, Naming Test (Low Frequency), Memory of Words Test, Recall of Drawings, Wechsler Memory Scale (Logical Memory, Associative Learning, and Total Score), Rey-Osterrieth Complex Figure (Immediate Recall Condition), Boston Diagnostic Aphasia Examination (Complex Ideational Material Subtest), Memory of Three Phrases Test, Serial Verbal Learning (maximum score and Delayed Recall), Knopman Test (First Trial, Second Trial, and Recall after 5 Minutes), Digit Symbol, and Visual "A" Cancellation Test (Additions). Results supported the hypothesis that memory complaints represent the earliest symptom of familial Alzheimer's disease. In addition to the memory difficulties, other minor cognitive impairments were also found, particularly, mild anomia, concentration difficulties and defects in the understanding of complex verbal material.

Entities:  

Year:  2000        PMID: 14590205

Source DB:  PubMed          Journal:  Arch Clin Neuropsychol        ISSN: 0887-6177            Impact factor:   2.813


  12 in total

1.  Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease.

Authors:  Yakeel T Quiroz; Andrew E Budson; Kim Celone; Adriana Ruiz; Randall Newmark; Gabriel Castrillón; Francisco Lopera; Chantal E Stern
Journal:  Ann Neurol       Date:  2010-12       Impact factor: 10.422

2.  Genetic origin of a large family with a novel PSEN1 mutation (Ile416Thr).

Authors:  Laura Ramirez Aguilar; Juliana Acosta-Uribe; Margarita M Giraldo; Sonia Moreno; Ana Baena; Diana Alzate; Rosario Cuastumal; David Aguillón; Lucía Madrigal; Amanda Saldarriaga; Alexander Navarro; Gloria P Garcia; Daniel C Aguirre-Acevedo; Ethan G Geier; J Nicholas Cochran; Yakeel T Quiroz; Richard M Myers; Jennifer S Yokoyama; Kenneth S Kosik; Francisco Lopera
Journal:  Alzheimers Dement       Date:  2019-02-10       Impact factor: 21.566

3.  Biological and Cognitive Markers of Presenilin1 E280A Autosomal Dominant Alzheimer's Disease: A Comprehensive Review of the Colombian Kindred.

Authors:  J T Fuller; A Cronin-Golomb; J R Gatchel; D J Norton; E Guzmán-Vélez; H I L Jacobs; B Hanseeuw; E Pardilla-Delgado; A Artola; A Baena; Y Bocanegra; K S Kosik; K Chen; P N Tariot; K Johnson; R A Sperling; E M Reiman; F Lopera; Y T Quiroz
Journal:  J Prev Alzheimers Dis       Date:  2019

Review 4.  Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments.

Authors:  Eric M Reiman; Jessica B S Langbaum; Adam S Fleisher; Richard J Caselli; Kewei Chen; Napatkamon Ayutyanont; Yakeel T Quiroz; Kenneth S Kosik; Francisco Lopera; Pierre N Tariot
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

5.  Event-related potential markers of brain changes in preclinical familial Alzheimer disease.

Authors:  Y T Quiroz; B A Ally; K Celone; J McKeever; A L Ruiz-Rizzo; F Lopera; C E Stern; A E Budson
Journal:  Neurology       Date:  2011-07-20       Impact factor: 9.910

Review 6.  Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene.

Authors:  A J Larner; M Doran
Journal:  J Neurol       Date:  2005-11-04       Impact factor: 6.682

7.  Memory binding and white matter integrity in familial Alzheimer's disease.

Authors:  Mario A Parra; Heini Saarimäki; Mark E Bastin; Ana C Londoño; Lewis Pettit; Francisco Lopera; Sergio Della Sala; Sharon Abrahams
Journal:  Brain       Date:  2015-03-11       Impact factor: 13.501

8.  P300 and neuropsychological assessment in mild cognitive impairment and Alzheimer dementia.

Authors:  Mario A Parra; Lindsay Lorena Ascencio; Hugo Fenando Urquina; Facundo Manes; Agustín M Ibáñez
Journal:  Front Neurol       Date:  2012-12-05       Impact factor: 4.003

9.  Subjective Cognitive Decline and its Relation to Verbal Memory and Sex in Cognitively Unimpaired Individuals from a Colombian Cohort with Autosomal-Dominant Alzheimer's Disease.

Authors:  Jairo E Martinez; Enmanuelle Pardilla-Delgado; Edmarie Guzmán-Vélez; Clara Vila-Castelar; Rebecca Amariglio; Jennifer Gatchel; Daniel C Aguirre-Acevedo; Yamile Bocanegra; Ana Baena; Eliana Henao; Victoria Tirado; Claudia Muñoz; Margarita Giraldo-Chica; Francisco Lopera; Yakeel T Quiroz
Journal:  J Int Neuropsychol Soc       Date:  2021-06-30       Impact factor: 3.114

Review 10.  Clinical, biological, and imaging features of monogenic Alzheimer's Disease.

Authors:  Andrea Pilotto; Alessandro Padovani; Barbara Borroni
Journal:  Biomed Res Int       Date:  2013-11-27       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.